International journal of surgery (London, England)
Triple adjuvant therapy with transarterial chemoembolizaition, lenvatinib, and programmed death-1 inhibitors improves short-term recurrence control in high-risk patients with resected intermediate-stage hepatocellular carcinoma.
Guanhua Chen, Yiwen Qiu, Shu Shen, Jianchen Luo, Dongdong Zhu, Wentao Wang
Published: 202510.1097/JS9.0000000000004088
Abstract
BACKGROUND: Intermediate-stage hepatocellular carcinoma (HCC) following curative liver resection (LR) is associated with high recurrence rates and poor survival outcomes. Current studies have found that transarterial chemoembolization can improve ove…
Preview only. Read the full abstract at the source